Management & Business Advisors
WALTER V. KLEMP
President, CEO and Chairman
Walter Klemp has been our Co-Founder, Chairman and CEO since 2007. Mr. Klemp has 29 years of experience in start-up and high-growth companies, the past nine of which have been spent developing FDA-approved dermatology therapy devices and topical compounds.
Mr. Klemp was also President and CEO of Zeno Corporation from 2004 to 2010, where he successfully developed and marketed a number of dermatology devices and drugs from concept through FDA approval.
Previously, Mr. Klemp served as Founder, CEO and Chairman of Drypers Corporation, a publicly traded multinational consumer products company, from 1987 to 2000. At Drypers, Mr. Klemp developed growth strategies, orchestrated mergers and acquisitions, and grew the company from start-up to $400 million in annualized sales and to a #1 ranking on the INC 500. Notably, he has overseen nearly $750 million in public and private financings throughout his career.
DONALD PICKER, PHD
Chief Science Officer
Donald Picker, PhD, joined the Moleculin team in 2009 with over 35 years of drug development experience. At Johnson Matthey, Dr. Picker was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, acquired by Bristol-Myers Squibb and with annual sales of over $500 million. He also oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.
Dr. Picker has significant experience in dermatological pharmaceutical discovery and development as well, having led projects for topical therapies in psoriasis, atopic dermatitis and acne.
ROBERT SHEPARD, MD, FACP
Chief Medical Officer
Dr. Robert Shepard has extensive research credentials in hematology and oncology and is board certified in oncology, hematology and internal medicine. He has a wide array of experience in translational medicine and clinical research and has been actively involved in oncology research since 1970, responsible for the complete clinical development of several drugs and immune therapies for biopharmaceutical companies, including serving as the consulting Chief Medical Officer for six companies. Dr. Shepard is a Magna Cum Laude graduate of Harvard University in biochemical sciences and molecular biophysics and studied in the Harvard-M.I.T. Health Sciences program. He held fellowships in hematology and oncology at the Tufts-New England Medical Center where he conducted laboratory research in leukemias, myeloma and myelodysplasia, as well as fellowship in pharmacology and molecular genetics at the Dana-Farber Cancer Center and Harvard Medical School. Dr. Shepard holds academic appointments at Harvard University, Tufts University and the University of Virginia.
JONATHAN P. FOSTER
Executive VP & Chief Financial Officer
Jonathan P. Foster joined Moleculin in August 2016. Previously, Mr. Foster was with InfuSystem Holdings, Inc., an NYSE MKT listed company and a leading national provider of infusion pumps and related services to the healthcare industry in the United States and Canada, primarily related to the treatment of cancer, where he served as Executive Vice President and Chief Financial Officer, since 2012. He brings more than 30 years in financial experience holding a variety of executive and senior financial positions with public, private, start-up to large corporate and international companies.
At InfuSystem Holdings, Inc., Mr. Foster joined in early 2012 during an Activist takeover and served through multiple subsequent Board and CEO transitions. While working in a close team environment, Mr. Foster led the implementation of accounting, budgeting, corrections of material weaknesses, improvements in internal control and cash control discipline, investigations of strategic alternatives and execution on multiple refinancings. Such actions resulted in revenue growth and a return to profitability. From March 2012 to March 2016, InfuSystem lowered its effective interest rate on its debt from over 18% to under 3% and increased its Enterprise Value by over 50%.
Prior to InfuSystem, Mr. Foster served as a consultant to the Chief Financial Officer of LSG Sky Chefs, USA, Inc., a subsidiary of Deutsche Lufthansa AG and the world’s largest provider of airline catering and in-flight services. Prior to that, from 2000-2012, he was President, CFO and majority owner of United Credit, Inc. & Advance Today, Inc., a privately owned consumer finance company with multiple locations. During his time there, Mr. Foster successfully doubled revenue, tripled the firm’s loan base and strengthened business operations and profitability.
From 1996-2000, Mr. Foster served as Executive Vice President and Chief Financial Officer of Drypers Corporation, a publicly traded global consumer products company with more than 2,000 employees internationally and $460 million in revenue, where he worked alongside Moleculin’s Chairman and Acting CEO, Walter Klemp.
He previously served as Chief Financial Officer of Dickson Weatherproof Nail Company, Controller & Treasurer of divisions of Schlumberger Industries, and as a Manager in the Middle Market Group of Deloitte & Touche. He has also served on the State of South Carolina Board of Financial Institutions and the Board of Directors for the Easley Baptist Hospital Foundation.
Mr. Foster has a BS in Accounting from Clemson University, is a Certified Public Accountant and AICPA Chartered Global Management Accountant.
LORI H. BISSON
Business Advisory Board Member
Lori Bisson is a Co-Founder of Moleculin, a Director and our acting CFO. Ms. Bisson brings a wealth of experience in consumer products and regulated environments from her tenure with both Zeno Corporation and Drypers Corporation. She also serves as the CFO for a medical device company.
Previously, Ms. Bisson was CFO of Zeno Corporation from 2005 to 2008. She also served as CFO of Gulfstream Trading, Ltd., a privately held $1.5 billion oil trading company.
Ms. Bisson received her CPA license while working as an auditor with Arthur Andersen.